^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    epertinib (S-222611)

    i
    Other names: S-222611, S 222611, EOC611, EOC 611, EOC-611, S222611
    Company:
    EOC Pharma, Shionogi
    Drug class:
    EGFR inhibitor, HER2 inhibitor
    Related drugs:
    1m
    Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2. (PubMed, Biomed Pharmacother)
    In summary, our study demonstrates an additional pharmacological capability of epertinib against the activity of ABCB1 and ABCG2. These findings suggest that incorporating epertinib into combination therapy could be advantageous for a specific patient subset with tumors exhibiting high levels of ABCB1 or ABCG2, warranting further exploration.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    ABCB1 overexpression • ABCG2 expression
    |
    epertinib (S-222611)